Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03345004
Other study ID # DIAGNODE-2 (D/P2/17/6)
Secondary ID 2017-001861-25
Status Completed
Phase Phase 2
First received
Last updated
Start date December 20, 2017
Est. completion date April 27, 2021

Study information

Verified date April 2022
Source Diamyd Medical AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous insulin secretion as measured by C-peptide.


Description:

The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial. Eligible patients will receive injections of Diamyd/placebo into an inguinal lymph gland at three occasions, with one month intervals in combination with an oral vitamin D/placebo regimen (starting 1 month ahead of injections) during 4 months. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period. The patients will be followed in a blinded manner for a total of 15 months. All patients that have not performed the 15 months visit when the updated protocol is implemented, will be asked to participate in the Extension Study Period which includes an additional visit at month 24.


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date April 27, 2021
Est. primary completion date July 13, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Years to 24 Years
Eligibility Inclusion Criteria: 1. Informed consent given by patients and/or patient's parent(s) or legal acceptable representative(s) (guardian(s)) according to national regulations 2. Type 1 Diabetes (T1D) according to the Amercian Diabetes Association (ADA) classification diagnosed =6 months at the time of screening 3. Age: =12 and <25 years old 4. Fasting C-peptide =0.12 nmol/L (0.36 ng/ml) on at least one occasion (maximum 2 tests on different days within a period of 2 weeks) 5. Positive for Glutamic Acid Decarboxylase isoform 65 (GAD65A) but < 50 000 IU/ml 6. Females must agree to avoid pregnancy and have a negative urine pregnancy test. Patients of childbearing potential must agree to use adequate contraception, until one (1) year after the last administration of Diamyd. Adequate contraception is as follows: For females of childbearing potential: 1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives 2. combined (estrogen and progestogen containing) 3. oral, intravaginal or transdermal progesterone hormonal contraception associated with inhibition of ovulation 4. intrauterine device 5. intrauterine hormone-releasing system (for example, progestin-releasing coil) 6. bilateral tubal occlusion 7. vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate) 8. male partner using condom 9. abstinence from heterosexual intercourse For males of childbearing potential: 1. condom (male) 2. abstinence from heterosexual intercourse Exclusion Criteria: 1. Previous or current treatment with immunosuppressant therapy (although topical or inhaled steroids are accepted) 2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted) 3. Treatment with any oral or injected anti-diabetic medications other than insulin 4. A history of anemia or significantly abnormal hematology results at screening 5. A history of epilepsy, head trauma or cerebrovascular accident, or clinical features of continuous motor unit activity in proximal muscles 6. Clinically significant history of acute reaction to vaccines or other drugs in the past 7. Treatment with any vaccine, including influenza vaccine, within 4 months prior to planned first study drug dose or planned treatment with any vaccine up to 4 months after the last injection with study drug. 8. Participation in other clinical trials with a new chemical entity within the previous 3 months 9. Inability or unwillingness to comply with the provisions of this protocol 10. A history of alcohol or drug abuse 11. A significant illness other than diabetes within 2 weeks prior to first dosing 12. Known HIV or hepatitis 13. Females who are lactating or pregnant (the possibility of pregnancy must be excluded by urine ßHCG on-site within 24 hours prior to the Diamyd/placebo treatment) 14. Presence of associated serious disease or condition, including active skin infections that preclude intralymphatic injection, which in the opinion of the investigator makes the patient non-eligible for the study 15. Deemed by the investigator not being able to follow instructions and/or follow the study protocol

Study Design


Intervention

Biological:
Diamyd
Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
Dietary Supplement:
Vitamin D
Oil suspension of Vitamin D
Biological:
Placebo for Diamyd
Alhydrogel® only
Dietary Supplement:
Placebo for Vitamin D
Placebo oil suspension for Vitamin D

Locations

Country Name City State
Czechia Department of Paediatrics, University Hospital Motol Praha
Czechia Diabetes Centre, Institute of Clinical and Experimental Medicine Praha
Netherlands Diabeter Rotterdam Rotterdam
Spain Adult and Pediatrics Endocrinology and Diabetology, Hospital Universitario Cruces Barakaldo
Spain Adult Endocrinology and Diabetology, Hospital vall D' Hebrón Barcelona
Spain Pediatrics Endocrinology and Diabetology, Hospital Vall D'Hebrón Barcelona
Spain Adult Endocrinology and Diabetology, Hospital Ramón y Cajal Madrid
Spain Adult Endocrinology and Diabetology, Hospital Carlos Haya Málaga
Spain Pediatrics Endocrinology and Diabetology, Hospital Materno-Ifantil Málaga
Spain Adult Endocrinology and Diabetology, Hospital Macarena Sevilla
Spain Pediatrics Endocrinology and Diabetology, Hospital Virgen del Rocío Sevilla
Spain Adult and Pediatrics Endocrinology and Diabetology, Hospital Miguel Servet Zaragoza
Sweden Barn- och Ungdomskliniken, Universitetssjukhuset Linköping
Sweden Endokrinmedicinska kliniken. Universitetssjukhuset Linköping
Sweden Barn-och Ungdomsmedicinmottagningen and Endokrinmottagningen, Skånes Universitetssjukhus Malmö
Sweden Barn- och ungdomskliniken, Uddevalla Sjukhus Uddevalla
Sweden Diabetesmottagningen, Uddevalla Sjukhus Uddevalla
Sweden Barnmottagningen, Norrlands Universitetssjukhus Umeå

Sponsors (1)

Lead Sponsor Collaborator
Diamyd Medical AB

Countries where clinical trial is conducted

Czechia,  Netherlands,  Spain,  Sweden, 

References & Publications (2)

Ludvigsson J, Tavira B, Casas R. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med. 2017 Jul 27;377(4):403-5. doi: 10.1056/NEJMc1703468. No abstract available. — View Citation

Ludvigsson J, Wahlberg J, Casas R. Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med. 2017 Feb 16;376(7):697-699. doi: 10.1056/NEJMc1616343. No abstract available. Erratum In: N Engl J Med. 2017 Jul 27;377(4):405. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Stimulated C-peptide During a MMTT Change in C-peptide between Baseline and 15 Months. C-peptide was measured by Area Under the Curve [AUC] at 0-120 min during a Mixed Meal Tolerance Test (MMTT) and divided by 120 min. The results are given as the ratio (back-transformed from log-scale) between 15 Months and Baseline as predicted by the MMRM (Mixed Model Repeated Measures) model. Baseline and 15 months
Secondary Change in IDAA1c Change in insulin-dose-adjusted HbA1c (IDAA1c) Baseline and 15 months
Secondary Change in HbA1c Change in HbA1c (mmol/mol) Baseline and 15 months
Secondary Change in Insulin Consumption Change in daily exogenous insulin consumption (IU) Baseline and 15 months
Secondary Change in Glycemic Variability/Fluctuations Change in glycemic variability/fluctuations (evaluated from data from continuous glucose monitoring FreeStyle LibrePro, FGM) over 14 day period. Screening and 15 months
Secondary Percentage of Patients With IDAA1c = 9 Percentage of patients with IDAA1c = 9 15 months
Secondary Stimulated Maximum C-peptide Above 0.2 Nmol/L Percentage of patients with a stimulated maximum C-peptide level above 0.2 nmol/L (0.6 ng/ml) 15 months
Secondary Stimulated C-peptide Above 0.2 Nmol/L at 90 Min Percentage of patients with a stimulated 90min C-peptide level above 0.2 nmol/L (0.6 ng/ml) 15 months
Secondary Number of Hypoglycemias Number of self-reported episodes of severe hypoglycemia (Severe hypoglycemia defined as needing help from others and/or seizures and/or unconscious) (counts) Baseline and 15 months
Secondary Number of Patients Having at Least 1 Severe Hypoglycemic Event Number of patients having at least 1 severe hypoglycemic event (counts) Baseline and 15 months
Secondary Change in Maximum C-peptide Change in maximum C-peptide during MMTT (nmol/L) Baseline and 15 months
Secondary Change in Fasting C-peptide Change in Fasting C-peptide (nmol/L) Baseline and 15 months
Secondary C-peptide Levels During a MMTT C-peptide measured at 30, 60, 90, and 120 minutes during MMTT (nmol/L) at 15 months 15 months
Secondary Change in Body Weight Change in body weight (kg) Baseline and 15 months
Secondary Injection Site Reactions Injection site reactions 15 months
Secondary Number of Clinically Significant Abnormal Results From Laboratory Measurements (Haematology and Clinical Chemistry) and Urinalysis. Number of clinically significant abnormal results from laboratory measurements (haematology and clinical chemistry) and urinalysis. (counts) 15 months
Secondary Number of Clinically Significant Abnormal Results From Physical and Neurological Examinations Physical examination (general appearance including skin, mouth, throat, cardiovascular, abdomen, lymphatic glands, and neurological/musculoskeletal [including reflexes]).
Standardised clinical neurological examination including extremity reflexes, Romberg, Walk on a line, 2 meters, Standing on 1 leg, left and right, 15 seconds per leg, Finger-nose, Mimic, Babinski reflex.
The outcome of the assessments was recored as "normal" or "abnormal"
15 months
Secondary GAD65A Titer GAD65A titer (IU/ml) Baseline and 15 months
Secondary Number of Clinically Significant Abnormal Results in Vital Signs Vital signs (blood pressure) (mmHg) 15 months
Secondary Change in Quality of Life (QoL) Change in QoL as measured by the standardised measure of health questionnaire EQ-5D-5L between baseline and Month 15. The EQ-5D-5L is based on 5 questions rated at 5 levels indicating from no problem (level 1) to extreme problems (level 5) regarding current state of mobility, self-care, activity, pain and anxiety. The outcome is presented as a weighted index value, where 1 is the best possible health and 0 represents being dead. Baseline and 15 months
Secondary Change in Body Mass Index (BMI) Change in BMI (kg/m2) Baseline and 15 months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A